Gynecological Sentinel Lymph Nodes CEUS

PRIMARY OBJECTIVES:

I. To determine the concordance between lymphosonography and the standard of care in the identification sentinel lymph nodes (SLNs) in patients with cervical, vaginal or vulvar cancer.

II. To determine if lymphosonography can identify more SLNs with metastatic deposits in patients with cervical, vaginal or vulvar cancer when compared to the standard of care.

OUTLINE:

Patients receive perflubutane microbubble (Sonazoid) injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.

After completion of study intervention, patients are followed up for 30 days.

Inclusion criteria

• Be female
• Be diagnosed with cervical, vaginal or vulvar cancer
• Be at least 18 years of age
• If of child-bearing potential, must have a negative pregnancy test
• Be able to comply with study procedures
• Have read and signed the Institutional Review Board (IRB)-approved informed consent form for participating in the study

Exclusion criteria

• Females who are pregnant or nursing
• Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards
• Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example:

• Patients on life support or in a critical care unit
• Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia
• Patients with recent cerebral hemorrhage
• Patients who have undergone surgery within 24 hours prior to the study sonographic examination
• Patients with congenital heart defects
• Patient with a known allergy to Sonazoid (including an anaphylactic allergy to eggs or egg products)